Academic Psychiatry

, Volume 29, Issue 2, pp 162–166 | Cite as

Old Versus New Medications: How Much Should Be Taught?




To address the issue of how much psychiatric residents should be taught about older medications.


Selective use of the literature, including historical overview was employed to compare and contrast old and newer generation medications.


While many old drugs are truly antiquated, medications such as typical antipsychotics tricyclic and monoamine oxidase antidepressants, and lithium should remain integral parts of a psychopharmacology teaching program.


A proper blending of knowledge about older and newer medications and the use of older and newer medications is in the best interest of patients in need of psychopharmcotherapy.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Stauss MB (Ed.): Familiar Medical Quotations. Boston, Little, Brown and Company, 1968Google Scholar
  2. 2.
    Jefferson JW: Old drugs for old folks. Geriatric Times 2000; 1: 13–14Google Scholar
  3. 3.
    Rush B: Medical Inquiries and Observations upon The Diseases of the Mind (facsimile of the Philadelphia 1812 ed.). New York, Hafner Publishing Company, 1962, 174–213Google Scholar
  4. 4.
    Feldman PE: Ancient psychopharmacotherapy. Bull Menninger Clin 1965; 2: 256–263Google Scholar
  5. 5.
    Davidson JRT, Abraham K, Connor KM, et al: Effectiveness of chromium in atypical depression: a placebo-controlled trial. Biol Psychiatry 2003; 53: 261–264PubMedCrossRefGoogle Scholar
  6. 6.
    Ban TA: Pharmacotherapy of mental illness: a historical analysis. Prog Neuro-Psychopharmacol Biol Psychiatry 2001; 25: 709–727CrossRefGoogle Scholar
  7. 7.
    MacLeod N: The bromide sleep: a new departure in the treatment of acute mania. Br Med J 1900; 1: 134–136PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Bodkin JA, Zornberg GL, Lukas SE, Cole JO: Buprenorphine treatment of refractory depression. J Clin Psychopharmacol 1994; 15: 49–57CrossRefGoogle Scholar
  9. 9.
    Warneke, L: A possible new treatment approach to obsessive-compulsive disorder (Letter to Ed.). Can J Psychiatry 1997; 42: 667–668PubMedGoogle Scholar
  10. 10.
    Jefferson, JW: Who put the benzedrine in Mrs. Murphy’s oval-tine? Geriatric Times 2001; Sept/Oct: 9–10Google Scholar
  11. 11.
    Dwight-Johnson M, Lagomasino IT, Simpson GM: Underuse of evidence-based pharmacotherapies for affective disorders. Psychiatr Serv 2003; 54: 1076–1078PubMedCrossRefGoogle Scholar
  12. 12.
    Partial Agonism: Redefining Effectiveness Across the Spectrum of Psychotic Disorders. Irvine, Calif., CME Inc., 2003, pp 1–72Google Scholar
  13. 13.
    American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity: Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27(2): 596–601CrossRefGoogle Scholar
  14. 14.
    Geddes J, Freemantle N, Harrison P, et al: Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000; 321: 1371–1376PubMedCrossRefGoogle Scholar
  15. 15.
    Davis JM, Chen N, Glick RD: A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003; 60: 553–564PubMedCrossRefGoogle Scholar
  16. 16.
    Leucht S, Wahlbeck K, Hamann J, Kissling W: New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003; 361: 1581–1589PubMedCrossRefGoogle Scholar
  17. 17.
    Rosenheck R, Perlick D, Bingham S, et al: Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia. JAMA 2003; 290: 2693–2702PubMedCrossRefGoogle Scholar
  18. 18.
    Anderson IM: Meta-analytical studies on new antidepressants. Br Med J 2001; 57: 161–178Google Scholar
  19. 19.
    Sindrup SH, Jensen TS: Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 1999; 83: 389–400PubMedCrossRefGoogle Scholar
  20. 20.
    Geddes J, Goodwin G: Bipolar disorder: clinical uncertainty, evidence-based medicine and large-scale randomised trials. B J Psychiatry 178(suppl 41): 191–194, 2001CrossRefGoogle Scholar
  21. 21.
    Goodwin FK: Pharmacotherapy of bipolar disorder: trends and controversies (interview). Currents in Affective Illness 2001; 20: 5–11Google Scholar
  22. 22.
    Baldessarini RJ, Tondo L, Hennen J, et al: Is lithium still worth using? An update of selected recent research. Harv Rev Psychiatry 2002; 10: 59–75PubMedCrossRefGoogle Scholar
  23. 23.
    Tondo L, Isacsson G, Baldessarini RJ: Suicidal behaviour in bipolar disorder: risk and prevention. CNS Drugs 2003; 17: 491–511PubMedCrossRefGoogle Scholar
  24. 24.
    Healy D: The Anti-Depressant Era. Cambridge, Mass. and London, Harvard University Press, 1997Google Scholar
  25. 25.
    Partington A (Ed.): The Oxford Dictionary of Quotations. 4th Edition, N.Y., Oxford University Press, 1992Google Scholar

Copyright information

© Academic Psychiatry 2005

Authors and Affiliations

  1. 1.Madison Institute of Medicine, Inc.MadisonUSA
  2. 2.University of Wisconsin Medical SchoolMadisonUSA

Personalised recommendations